Ribozymes for treating hepatitis C
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 22, 2000
Issued Date -
N/A
app pub date -
Sep 11, 1995
filing date -
Dec 14, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Adenoviral vectors are used for high efficiency transduction of ribozymes specific for hepatitis C virus RNA. Hepatocytes are transduced with a recombinant adenovirus vector that expresses a ribozyme capable of specifically cleaving HCV RNA. The compositions and methods thus provide new means for treating HCV, and further provide transgenic non-human animals having human hepatocytes which are useful in models of HCV disease for developing therapeutic and preventative agents.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully